vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and FVCBankcorp, Inc. (FVCB). Click either name above to swap in a different company.
FVCBankcorp, Inc. is the larger business by last-quarter revenue ($16.9M vs $9.2M, roughly 1.8× Foghorn Therapeutics Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs 223.8%). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 35.3%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
FHTX vs FVCB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $16.9M |
| Net Profit | $-21.7M | — |
| Gross Margin | — | — |
| Operating Margin | -258.2% | 43.7% |
| Net Margin | -234.3% | — |
| Revenue YoY | 223.8% | 4377.5% |
| Net Profit YoY | -11.1% | — |
| EPS (diluted) | $-0.35 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $16.9M | ||
| Q3 25 | $8.2M | $416.0K | ||
| Q2 25 | $7.6M | $15.8M | ||
| Q1 25 | $6.0M | $382.0K | ||
| Q4 24 | $2.9M | $378.0K | ||
| Q3 24 | $7.8M | $412.0K | ||
| Q2 24 | $6.9M | $415.0K | ||
| Q1 24 | $5.0M | $359.0K |
| Q4 25 | $-21.7M | — | ||
| Q3 25 | $-15.8M | $5.6M | ||
| Q2 25 | $-17.9M | $5.7M | ||
| Q1 25 | $-18.8M | $5.2M | ||
| Q4 24 | $-19.5M | — | ||
| Q3 24 | $-19.1M | $4.7M | ||
| Q2 24 | $-23.0M | $4.2M | ||
| Q1 24 | $-25.0M | $1.3M |
| Q4 25 | -258.2% | 43.7% | ||
| Q3 25 | -226.9% | — | ||
| Q2 25 | -279.2% | 45.9% | ||
| Q1 25 | -385.0% | — | ||
| Q4 24 | -840.5% | — | ||
| Q3 24 | -305.5% | — | ||
| Q2 24 | -386.6% | — | ||
| Q1 24 | -558.3% | — |
| Q4 25 | -234.3% | — | ||
| Q3 25 | -194.4% | 1341.1% | ||
| Q2 25 | -237.3% | 36.0% | ||
| Q1 25 | -316.4% | 1352.1% | ||
| Q4 24 | -682.9% | — | ||
| Q3 24 | -244.9% | 1133.3% | ||
| Q2 24 | -333.6% | 1001.2% | ||
| Q1 24 | -495.4% | 373.3% |
| Q4 25 | $-0.35 | $0.31 | ||
| Q3 25 | $-0.25 | $0.31 | ||
| Q2 25 | $-0.28 | $0.31 | ||
| Q1 25 | $-0.30 | $0.28 | ||
| Q4 24 | $-0.23 | $0.27 | ||
| Q3 24 | $-0.31 | $0.25 | ||
| Q2 24 | $-0.45 | $0.23 | ||
| Q1 24 | $-0.59 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $253.6M |
| Total Assets | $198.1M | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | — | ||
| Q3 25 | $89.3M | — | ||
| Q2 25 | $72.6M | — | ||
| Q1 25 | $61.0M | — | ||
| Q4 24 | $55.5M | — | ||
| Q3 24 | $57.7M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $79.3M | — |
| Q4 25 | $-108.5M | $253.6M | ||
| Q3 25 | $-89.7M | $249.8M | ||
| Q2 25 | $-76.7M | $243.2M | ||
| Q1 25 | $-61.7M | $242.3M | ||
| Q4 24 | $-45.5M | $235.4M | ||
| Q3 24 | $-28.3M | $230.8M | ||
| Q2 24 | $-14.3M | $226.5M | ||
| Q1 24 | $-97.5M | $220.7M |
| Q4 25 | $198.1M | $2.3B | ||
| Q3 25 | $205.0M | $2.3B | ||
| Q2 25 | $226.2M | $2.2B | ||
| Q1 25 | $258.7M | $2.2B | ||
| Q4 24 | $284.0M | $2.2B | ||
| Q3 24 | $308.4M | $2.3B | ||
| Q2 24 | $328.6M | $2.3B | ||
| Q1 24 | $255.0M | $2.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $23.9M |
| Free Cash FlowOCF − Capex | — | $23.8M |
| FCF MarginFCF / Revenue | — | 140.7% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $40.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $23.9M | ||
| Q3 25 | $-18.9M | $7.6M | ||
| Q2 25 | $-21.0M | $3.3M | ||
| Q1 25 | $-24.0M | $5.4M | ||
| Q4 24 | $-24.5M | $18.2M | ||
| Q3 24 | $-21.0M | $4.7M | ||
| Q2 24 | $-25.5M | $1.6M | ||
| Q1 24 | $-29.3M | $7.2M |
| Q4 25 | — | $23.8M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $-21.0M | $3.3M | ||
| Q1 25 | $-24.0M | $5.4M | ||
| Q4 24 | $-25.0M | $18.1M | ||
| Q3 24 | $-21.3M | $4.6M | ||
| Q2 24 | $-25.6M | $1.5M | ||
| Q1 24 | $-29.4M | $7.1M |
| Q4 25 | — | 140.7% | ||
| Q3 25 | — | 1818.0% | ||
| Q2 25 | -278.2% | 20.8% | ||
| Q1 25 | -403.2% | 1413.6% | ||
| Q4 24 | -875.3% | 4786.0% | ||
| Q3 24 | -273.0% | 1121.8% | ||
| Q2 24 | -371.0% | 361.2% | ||
| Q1 24 | -583.1% | 1988.3% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.3% | 0.1% | ||
| Q1 25 | 0.5% | 4.2% | ||
| Q4 24 | 16.8% | 37.3% | ||
| Q3 24 | 4.0% | 14.1% | ||
| Q2 24 | 0.2% | 12.8% | ||
| Q1 24 | 2.0% | 3.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.00× | ||
| Q2 24 | — | 0.37× | ||
| Q1 24 | — | 5.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
